Estimates Revisions Gilead Sciences, Inc. Buenos Aires S.E.
Stocks
GILD
ARBCOM4601C4
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 52,825.00 ARS | +2.62% |
|
+2.72% | +12.73% |
| 08-05 | Gilead Sciences Delivers 'Plenty' to Like in Q2, RBC Says | MT |
| 08-05 | Leerink Partners Adjusts Price Target on Gilead Sciences to $130 From $126 | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- GILD Stock
- GILD Stock
- Consensus Gilead Sciences, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
